Population pharmacokinetics of imipenem in critically ill patients with suspected ventilator-associated pneumonia and evaluation of dosage regimens

British Journal of Clinical Pharmacology

Volumn 78, Issue 5, 2014, Pages 1022-1034

  Couffignal, Camille ^a,b,d   Pajot, Olivier ^c   Laouénan, Cédric ^a,b   Burdet, Charles ^a,b   Foucrier, Arnaud ^a   Wolff, Michel ^a,b   Armand Lefevre, Laurence ^a,b   Mentré, France ^a,b   Massias, Laurent ^a,b  

^a BICHAT HOSPITAL   (France)

^b UNIVERSITÉ PARIS DIDEROT   (France)

^c CENTRE HOSPITALIER VICTOR DUPOUY   (France)

^d Recherche Clinique et   (France)

Author keywords

Critical care; Imipenem; Population pharmacokinetics; Ventilator associated pneumonia

Indexed keywords

ALBUMIN; AMIKACIN; IMIPENEM; ANTIINFECTIVE AGENT;

ADULT; AGED; ALBUMIN BLOOD LEVEL; ALGORITHM; ANTIBIOTIC THERAPY; ARTICLE; ARTIFICIAL VENTILATION; BACILLI; BLOOD SAMPLING; BODY WEIGHT; CONCENTRATION RESPONSE; CREATININE CLEARANCE; CRITICALLY ILL PATIENT; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; FEMALE; HUMAN; INTENSIVE CARE UNIT; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; MULTICENTER STUDY; OPEN STUDY; PROSPECTIVE STUDY; RENAL REPLACEMENT THERAPY; STEADY STATE; VENTILATOR ASSOCIATED PNEUMONIA; VERY ELDERLY; VOLUME OF DISTRIBUTION; BIOLOGICAL MODEL; BLOOD; CLINICAL TRIAL; CRITICAL ILLNESS; DOSE RESPONSE; DRUG EFFECTS; GRAM NEGATIVE BACTERIUM; INTRAVENOUS DRUG ADMINISTRATION; METABOLISM; MICROBIOLOGY; MIDDLE AGED; MONTE CARLO METHOD; PNEUMONIA, VENTILATOR-ASSOCIATED; STATISTICAL MODEL;

ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; CRITICAL ILLNESS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GRAM-NEGATIVE BACTERIA; HUMANS; IMIPENEM; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; MODELS, STATISTICAL; MONTE CARLO METHOD; PNEUMONIA, VENTILATOR-ASSOCIATED; PROSPECTIVE STUDIES;

EID: 84918790447     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/bcp.12435     Document Type: Article

References (40)

1. American Thoracic Society, Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005; 171: 388-416.
2. Joseph J, Rodvold KA. The role of carbapenems in the treatment of severe nosocomial respiratory tract infections. Expert Opin Pharmacother 2008; 9: 561-75.
3. Balfour JA, Bryson HM, Brogden RN. Imipenem/cilastatin: an update of its antibacterial activity, pharmacokinetics and therapeutic efficacy in the treatment of serious infections. Drugs 1996; 51: 99-136.
4. Wolff M, Joly-Guillou M, Pajot O. Les carbapénémes. Réanimation 2009; 18: (Suppl. 2): S199-208.
5. Lee LS, Kinzig-Schippers M, Nafziger AN, Ma L, Sörgel F, Jones RN, Drusano GL, Bertino JS. Comparison of 30-min and 3-h infusion regimens for imipenem/cilastatin and for meropenem evaluated by Monte Carlo simulation. Diagn Microbiol Infect Dis 2010; 68: 251-8.
6. Rodloff AC, Goldstein EJC, Torres A. Two decades of imipenem therapy. J Antimicrob Chemother 2006; 58: 916-29.
7. Mouton JW, Touzw DJ, Horrevorts AM, Vinks AA. Comparative pharmacokinetics of the carbapenems: clinical implications. Clin Pharmacokinet 2000; 39: 185-201.
8. Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998; 26: 1-10.
9. Zelenitsky SA, Ariano RE, Zhanel GG. Pharmacodynamics of empirical antibiotic monotherapies for an intensive care unit (ICU) population based on Canadian surveillance data. J Antimicrob Chemother 2011; 66: 343-9.
10. Roberts JA, Lipman J. Pharmacokinetic issues for antibiotics in the critically ill patient. Crit Care Med 2009; 37: 840-51.
11. Pea F, Viale P, Furlanut M. Antimicrobial therapy in critically ill patients: a review of pathophysiological conditions responsible for altered disposition and pharmacokinetic variability. Clin Pharmacokinet 2005; 44: 1009-34.
12. Mehrotra R, De Gaudio R, Palazzo M. Antibiotic pharmacokinetic and pharmacodynamic considerations in critical illness. Intensive Care Med 2004; 30: 2145-56.
13. Boucher BA, Wood GC, Swanson JM. Pharmacokinetic changes in critical illness. Crit Care Clin 2006; 22: 255-71.
14. Belzberg H, Zhu J, Cornwell EE III, Murray JA, Sava J, Salim A, Velmahos GC, Gill MA. Imipenem levels are not predictable in the critically ill patient. J Trauma 2004; 56: 111-7.
15. McKindley DS, Boucher BA, Hess MM, Croce MA, Fabian TC. Pharmacokinetics of aztreonam and imipenem in critically ill patients with pneumonia. Pharmacotherapy 1996; 16: 924-31.
16. Tegeder I, Schmidtko A, Bräutigam L, Kirschbaum A, Geisslinger G, Lötsch J. Tissue distribution of imipenem in critically ill patients. Clin Pharmacol Ther 2002; 71: 325-33.
17. Novelli A, Adembri C, Livi P, Fallani S, Mazzei T, De Gaudio AR. Pharmacokinetic evaluation of meropenem and imipenem in critically ill patients with sepsis. Clin Pharmacokinet 2005; 44: 539-49.
18. Sakka SG, Glauner AK, Bulitta JB, Kinzig-Schippers M, Pfister W, Drusano GL, Sorgel F. Population pharmacokinetics and pharmacodynamics of continuous versus short-term infusion of imipenem-cilastatin in critically ill patients in a randomized, controlled trial. Antimicrob Agents Chemother 2007; 51: 3304-10.
19. Jaruratanasirikul S, Sudsai T. Comparison of the Pharmacodynamics of Imipenem in Patients with Ventilator-Associated Pneumonia Following Administration by 2 or 0.5 H Infusion. J Antimicrob Chemother 2009; 63: 560-3.
20. Conil J-M, Georges B, Ruiz S, Rival T, Seguin T, Cougot P, Fourcade O, Houin G, Saivin Sylvie. Tobramycin disposition in ICU patients receiving a once daily regimen: population approach and dosage simulations. Br J Clin Pharmacol 2011; 71: 61-71.
21. Crandon JL, Ariano RE, Zelenitsky SA, Nicasio AM, Kuti JL, Nicolau DP. Optimization of meropenem dosage in the critically ill population based on renal function. Intensive Care Med 2011; 37: 632-8.
22. Garcia-Capdevila L, López-Calull C, Arroyo C, Moral MA, Mangues MA, Bonal J. Determination of imipenem in plasma by high-performance liquid chromatography for pharmacokinetic studies in patients. J Chromatogr B Biomed Sci App 1997; 692: 127-32.
23. Lavielle M, Mentré F. Estimation of Population Pharmacokinetic Parameters of Saquinavir in HIV Patients with the MONOLIX Software. J Pharmacokinet Pharmacodyn 2007; 34: 229-49.
24. Kuhn E, Lavielle M. Maximum likelihood estimation in nonlinear mixed effects models. Comput Stat Data Anal 2005; 49: 1020-38.
25. Samson A, Lavielle M, Mentré F. Extension of the SAEM algorithm to left-censored data in nonlinear mixed-effects model: application to HIV dynamics model. Comput Stat Data Anal 2006; 51: 1562-74.
26. Beal SL. Ways to fit a PK model with some data below the quantification limit. J Pharmacokinet Pharmacodyn 2001; 28: 481-504.
27. Le Gall JR, Lemeshow S, Saulnier F. A new Simplified Acute Physiology Score (SAPS II) based on a European/North American multicenter study. J Am Med Assoc 1993; 270: 2957-63.
28. Vincent JL, Moreno R, Takala J, Willatts S, De Mendonça A, Bruining H, Reinhart CK, Suter PM, Thijs LG. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med 1996; 22: 707-10.
29. Gómez CM, Cordingly JJ, Palazzo MG. Altered pharmacokinetics of ceftazidime in critically ill patients. Antimicrob Agents Chemother 1999; 43: 1798-802.
30. Pickering JW, Frampton CM, Walker RJ, Shaw GM, Endre ZH. Four hour creatinine clearance is better than plasma creatinine for monitoring renal function in critically ill patients. Crit Care Lond Engl 2012; 16: R107.
31. Herrera-Gutiérrez ME, Seller-Pérez G, Banderas-Bravo E, Muñoz-Bono J, Lebrón-Gallardo M, Fernandez-Ortega JF. Replacement of 24-h creatinine clearance by 2-h creatinine clearance in intensive care unit patients: a single-center study. Intensive Care Med 2007; 33: 1900-6.
32. Herget-Rosenthal S, Quellmann T, Linden C, Hollenbeck M, Jankowski V, Kribben A. How does late nephrological co-management impact chronic kidney disease-An observational study. Int J Clin Pract 2010; 64: 1784-92.
33. Mould DR, Upton RN. Basic concepts in population modeling, simulation, and model-based drug development-part 2: introduction to pharmacokinetic modeling methods. CPT Pharmacomet Syst Pharmacol 2013; 2: e38.
34. Thai H-T, Mentré F, Holford NHG, Veyrat-Follet C, Comets E. Evaluation of bootstrap methods for estimating uncertainty of parameters in nonlinear mixed-effects models: a simulation study in population pharmacokinetics. J Pharmacokinet Pharmacodyn 2014; 41: 15-33.
35. Bergstrand M, Hooker AC, Wallin JE, Karlsson MO. Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models. AAPS J 2011; 13: 143-51.
36. EUCAST. Breakpoint table for interpretation of MICs and zone diameters [Internet]. Available at http://www.eucast.org/(last accessed 25 November 2013).
37. Ribbing J, Nyberg J, Caster O, Jonsson EN. The lasso-a novel method for predictive covariate model building in nonlinear mixed effects models. J Pharmacokinet Pharmacodyn 2007; 34: 485-517.
38. Yoshizawa K, Ikawa K, Ikeda K, Kumon H, Ohge H, Morikawa N. Optimisation of imipenem regimens in patients with impaired renal function by pharmacokinetic-pharmacodynamic target attainment analysis of plasma and urinary concentration data. Int J Antimicrob Agents 2012; 40: 427-33.
39. De Paepe P, Belpaire FM, Buylaert WA. Pharmacokinetic and pharmacodynamic considerations when treating patients with sepsis and septic shock. Clin Pharmacokinet 2002; 41: 1135-51.
40. Tanigawara Y, Sato R, Morita K, Kaku M, Aikawa N, Shimizu K. Population pharmacokinetics of Arbekacin in patients infected with methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2006; 50: 3754-62.